Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04911062 · ClinicalTrials.gov registry record · Phase 2
HTX-011 in Spinal Surgery
A Phase 2 study, sponsored by Heron Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT04911062: Completed Phase 2 study, sponsored by Heron Therapeutics.
NCT04911062 is a Phase 2 study that has completed, run by Heron Therapeutics. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04911062, a Phase 2 study, has completed, sponsored by Heron Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter study in subjects undergoing an open lumbar decompression surgery.
Interventions
- DRUG HTX-011
- DEVICE Luer Lock Applicator
- DRUG Bupivacaine HCI without epinephrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-04-07 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 2 |
What the finished NCT04911062 record still lists
NCT04911062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 3 interventions - of which HTX-011 is the first listed.
NCT04911062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04911062 about?
NCT04911062 is a clinical study titled "HTX-011 in Spinal Surgery". This is a Phase 2, multicenter study in subjects undergoing an open lumbar decompression surgery.
What is the current status of trial NCT04911062?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2022-04-07. Estimated completion is 2022-08-26.
What interventions are being tested in trial NCT04911062?
The interventions under investigation include: HTX-011 (DRUG), Luer Lock Applicator (DEVICE), Bupivacaine HCI without epinephrine (DRUG).
Who is sponsoring clinical trial NCT04911062?
This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04911062's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI